(MedPage Today) — Benefits of infrequent zoledronate acid (Reclast) infusions were seen later rather than sooner for low-risk women, a secondary analysis of a randomized trial indicated.
Among 1,054 early post-menopausal women, those who received…
Source link : https://www.medpagetoday.com/endocrinology/osteoporosis/118114
Author :
Publish date : 2025-10-23 19:39:00
Copyright for syndicated content belongs to the linked Source.
